{"DataElement":{"publicId":"5607249","version":"1","preferredName":"IHC 2+ PVR Stain Result Percentage Integer","preferredDefinition":"Numeric representation of the percentage of ImmunohistochemistryÂ (IHC) staining of 2+ for Polio Virus Receptor (PVR).","longName":"PVR2+STN_PRCNT_INTGR","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"5607212","version":"1","preferredName":"Laboratory Procedure Immunohistochemistry Staining Method Poliovirus Receptor 2+ Staining Finding","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen._A finding of 2+ staining for poliovirus receptor in a sample.","longName":"2543047v1.0:5607210v1.0","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5607210","version":"1","preferredName":"Immunohistochemistry Staining Method Poliovirus Receptor 2+ Staining Finding","preferredDefinition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.:A finding of 2+ staining for poliovirus receptor in a sample.","longName":"C23020:C131117","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunohistochemistry Staining Method","conceptCode":"C23020","definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Poliovirus Receptor 2+ Staining Finding","conceptCode":"C131117","definition":"A finding of 2+ staining for poliovirus receptor in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"43CDFDE8-B372-6309-E053-F662850AB5B4","latestVersionIndicator":"Yes","beginDate":"2016-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-16","modifiedBy":"ONEDATA","dateModified":"2016-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435027","version":"1","preferredName":"Gene","preferredDefinition":"A functional unit of heredity which occupies a specific position (locus) on a particular chromosome, is capable of reproducing itself exactly at each cell division, and directs the formation of a protein or other product. The gene as a functional unit consists of a discrete segment of a giant DNA molecule containing the purine (adenine and guanine) and pyrimidine (cytosine and thymine) bases in the ordered and correct sequence that encodes a specific functional product (i.e., a protein or RNA molecule).","longName":"C16612","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB05-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"43CDFDE8-B383-6309-E053-F662850AB5B4","latestVersionIndicator":"Yes","beginDate":"2016-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-16","modifiedBy":"COOPERM","dateModified":"2016-12-19","changeDescription":"Created for IHC Monitoring form for brain cancer study in Rave as requested by M. Leonard. mc 12/16/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2434147","version":"1","preferredName":"Percentage Integer","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator._A number with no fractional part.","longName":"2434147v1","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":"0","maxLength":"3","minValue":"0","maxValue":"100","decimalPlace":null,"format":"%","PermissibleValues":[],"ConceptualDomain":{"publicId":"2183782","version":"1","preferredName":"NCIP","preferredDefinition":"Cancer Biomedical Informatics Grid","longName":"NCIP","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DACB2549-3BE3-73F7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2434146","version":"1","preferredName":"Percentage Integer","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator.:A number with no fractional part.","longName":"C25613:C45255","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"062E16DD-4FA5-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CAP PROTOCOLS:College of American Pathologists Cancer Protocols","workflowStatus":"RELEASED","registrationStatus":"Application","id":"062E16DD-4FA6-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2005-11-28","modifiedBy":"COOPERM","dateModified":"2016-12-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"2+ PVR Staining","type":"Preferred Question Text","description":"2+ PVR Staining","url":null,"context":"DCI"}],"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"43CEF06E-3E0E-5D29-E053-F662850A33F4","latestVersionIndicator":"Yes","beginDate":"2016-12-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-12-16","modifiedBy":"COOPERM","dateModified":"2016-12-19","changeDescription":"Created for IHC Monitoring form for brain cancer study in Rave as requested by M. Leonard. mc 12/16/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}